Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-30
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, double-blind, multicenter, positive control study to assess the efficacy, safety, and pharmacokinetics of Meropenem and Pralurbactam compared with Ceftazidime-avibactam in combination with Metronidazole in the treatment of adult complicated intra-abdominal infections (cIAI).
Phase:
PHASE3
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Treatments:
avibactam, ceftazidime drug combination Meropenem Metronidazole Sodium Chloride